It sounded like a really appealing approach at the time or a very innovative approach to make sure that medicine is personalized, is working and know that the medicine I’m taking is just for me.Nick Stump
It was clear there were not many options for Nick, but fortunately, he was eligible for a Phase 0 clinical trial at the Ivy Brain Tumor Center. Additional tumor genetic profiling of tissue from Nick’s first surgery was used to identify a new experimental drug therapy tailored specifically to the genetics of his tumor. This personalized therapy approach is a part of the accelerated Phase 0 clinical trials program at the Ivy Brain Tumor Center led by Dr. Nader Sanai. Nick started taking the new, first-in-class drug for five days before his second surgery, and afterward, Dr. Sanai and his team discovered the drug had reached the tumor successfully and modulated its target. With this evidence, Nick started taking the drug as part of a therapeutic treatment regimen following surgery.
“It sounded like a really appealing approach at the time or a very innovative approach to make sure that medicine is personalized, is working and know that the medicine I’m taking is just for me,” said Nick.
Nick’s tumor remains undetectable thanks to the rapid workflow and novel design of the Ivy Center’s Phase 0 clinical trial. The Ivy team identified that a recently-developed drug intended for aggressive breast cancer could penetrate the blood-brain barrier and target Nick’s brain tumor — a rare step forward in neuro-oncology. The Phase 0 clinical trial design also allowed the team to test the drug with success and individualize care in a fraction of the time and cost.
Nick is now focused on his future and is currently working in the medical field with the hopes that he can give back to patients like himself.
“I’m just extremely grateful for all the folks here at Barrow and the Ivy Center. I have nothing but positive things to say about them.”